DOSE — Rapid Dose Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapMomentum Trap

Annual income statement for Rapid Dose Therapeutics, fiscal year end - February 28th, CAD millions except per share, conversion factor applied.

	2019 February 28th	2020 February 29th	R2021 February 28th	2022 February 28th	2023 February 28th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0	0.102	0.755	1.75	0.718
Cost of Revenue
Gross Profit	—	0.037	0.7	1.34	0.372
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	11.5	7.72	2.53	10.3	4.53
Operating Profit	-11.5	-7.61	-1.78	-8.52	-3.81
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-11.4	-7.96	-1.81	-8.49	-3.81
Net Income After Taxes	-11.4	-7.96	-1.81	-8.49	-3.81
Net Income Before Extraordinary Items
Net Income	-11.4	-7.96	-1.81	-8.49	-3.81
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-11.4	-7.96	-1.81	-8.49	-3.81
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.051	-0.106	-0.022	-0.043	-0.037